Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Meehan RS"'
Autor:
Weber JS; Laura and Isaac Perlmutter Cancer Center at NYU Langone Health, New York, NY, USA. Electronic address: Jeffrey.Weber@nyulangone.org., Carlino MS; Westmead and Blacktown Hospitals, Melanoma Institute Australia, Sydney, NSW, Australia., Khattak A; Hollywood Private Hospital, Perth, WA, Australia; Edith Cowan University, Perth, WA, Australia., Meniawy T; Saint John of God Subiaco Hospital, Subiaco, WA, Australia., Ansstas G; Washington University School of Medicine, St Louis, MO, USA., Taylor MH; Earle A Chiles Research Institute, Providence Cancer Institute, Portland, OR, USA., Kim KB; California Pacific Medical Center Research Institute, San Francisco, CA, USA., McKean M; Sarah Cannon Research Institute at Tennessee Oncology, Nashville, TN, USA., Long GV; Melanoma Institute Australia, The University of Sydney, Sydney, NSW, Australia; Royal North Shore and Mater Hospitals, Sydney, NSW, Australia., Sullivan RJ; Massachusetts General Hospital, Harvard Medical School, Boston, MA, USA., Faries M; The Angeles Clinic and Research Institute, a Cedars-Sinai affiliate, Los Angeles, CA, USA., Tran TT; Smilow Cancer Center at Yale New Haven Hospital, New Haven, CT, USA., Cowey CL; Texas Oncology PA, Dallas, TX, USA., Pecora A; Hackensack University Medical Center, Hackensack, NJ, USA., Shaheen M; The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA., Segar J; University of Arizona, Tucson, AZ, USA., Medina T; University of Colorado Cancer Center, Aurora, CO, USA., Atkinson V; Princess Alexandra Hospital, Brisbane, QLD, Australia., Gibney GT; Georgetown-Lombardi Comprehensive Cancer Center, Washington, DC, USA., Luke JJ; UPMC Hillman Cancer Center, Pittsburgh, PA, USA., Thomas S; Orlando Health Kuhl Avenue, Orlando, FL, USA., Buchbinder EI; Dana-Farber Cancer Institute, Boston, MA, USA., Healy JA; Merck & Co, Rahway, NJ, USA., Huang M; Merck & Co, Rahway, NJ, USA., Morrissey M; Moderna, Cambridge, MA, USA., Feldman I; Moderna, Cambridge, MA, USA., Sehgal V; Moderna, Cambridge, MA, USA., Robert-Tissot C; Moderna, Cambridge, MA, USA., Hou P; Moderna, Cambridge, MA, USA., Zhu L; Moderna, Cambridge, MA, USA., Brown M; Moderna, Cambridge, MA, USA., Aanur P; Moderna, Cambridge, MA, USA., Meehan RS; Moderna, Cambridge, MA, USA., Zaks T; Moderna, Cambridge, MA, USA.
Publikováno v:
Lancet (London, England) [Lancet] 2024 Feb 17; Vol. 403 (10427), pp. 632-644. Date of Electronic Publication: 2024 Jan 18.
Autor:
Coyne GO; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Kummar S; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.; Current address: Knight Cancer Institute, Oregon Health Sciences University, Portland, OR, USA., Meehan RS; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Do K; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Collins JM; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA., Anderson L; Division of Cancer Treatment and Diagnosis, National Cancer Institute, Rockville, MD, USA., Ishii K; Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD, USA., Takebe N; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Zlott J; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Juwara L; Clinical Monitoring Research Program Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Piekarz R; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Streicher H; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Sharon E; Cancer Therapy Evaluation Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Rubinstein L; Biometric Research Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, Bethesda, MD, USA., Voth AR; Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Lozier J; Pediatric Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Dull AB; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Wilsker D; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Hinoue T; Van Andel Institute, Center for Epigenetics, Grand Rapids, MI, USA., Laird PW; Van Andel Institute, Center for Epigenetics, Grand Rapids, MI, USA., Ferry-Galow KV; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Kinders RJ; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Parchment RE; Clinical Pharmacodynamic Biomarkers Program, Applied/Developmental Research Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Doroshow JH; Division of Cancer Treatment and Diagnosis, and Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA., Chen AP; Early Clinical Trials Development Program, Division of Cancer Treatment and Diagnosis, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA.
Publikováno v:
Oncotarget [Oncotarget] 2020 Nov 03; Vol. 11 (44), pp. 3959-3971. Date of Electronic Publication: 2020 Nov 03 (Print Publication: 2020).
Autor:
Lee SY; Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.; Section of Hematology/Oncology, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA., Meehan RS; Section of Hematology/Oncology, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA., Seldin DC; Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.; Section of Hematology/Oncology, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA., Sloan JM; Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.; Section of Hematology/Oncology, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA., Quillen K; Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.; Section of Hematology/Oncology, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA., Shelton A; Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.; Section of Hematology/Oncology, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA., Brauneis D; Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.; Section of Hematology/Oncology, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA., Sanchorawala V; Amyloidosis Center, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.; Section of Hematology/Oncology, Boston University School of Medicine and Boston Medical Center, Boston, MA, USA.
Publikováno v:
Bone marrow transplantation [Bone Marrow Transplant] 2016 Oct; Vol. 51 (10), pp. 1318-1322. Date of Electronic Publication: 2016 May 16.
Autor:
Meehan RS; Early Clinical Trials Development Program Division of Cancer Treatment and Diagnosis (DCTD), National Institutes of Health (NIH) National Cancer Institute (NCI), 10 Center Drive, Bldg 31, 3A44, Bethesda, MD 20892 USA., Chen AP; Early Clinical Trials Development Program Division of Cancer Treatment and Diagnosis (DCTD), National Institutes of Health (NIH) National Cancer Institute (NCI), 10 Center Drive, Bldg 31, 3A44, Bethesda, MD 20892 USA.
Publikováno v:
Gynecologic oncology research and practice [Gynecol Oncol Res Pract] 2016 Feb 26; Vol. 3, pp. 3. Date of Electronic Publication: 2016 Feb 26 (Print Publication: 2016).